Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dexamethasone nanoparticles eye drops
Dexamethasone nanoparticles eye · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Dexamethasone nanoparticles eye drops | DRUG | DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks |
Top 16 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| 4D Molecular Therapeutics, Inc. | FDMT | 2 | PHASE3 | 4D-150, EYELEA |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Hoffmann-La Roche | RHHBY | 6 | PHASE3 | Ranibizumab, Susvimo, RO7497372, RO7823653, Faricimab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | MK-8748 |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | Surabgene Lomparvovec |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tabirafusp tedromer |
| Alvotech | ALVO | 1 | PHASE3 | AVT29 |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 |
| BioAge Labs, Inc. | BIOA | 1 | PHASE2 | BGE-102 |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Surrozen Inc | SRZN | 1 | PHASE1 | SZN-8141 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
| Bayer | BAYRY | 1 | - | Aflibercept |
Dexamethasone nanoparticles eye is an investigational topical eye drop formulation of dexamethasone, a small molecule corticosteroid, developed by Oculis Holding AG (ticker OCS). It is being studied for the treatment of diabetic macular edema, a complication of diabetes that causes swelling in the retina. The nanoparticle formulation is designed to deliver dexamethasone to the eye via eye drops.
Dexamethasone nanoparticles eye is being developed for the treatment of diabetic macular edema. This condition involves fluid accumulation in the macula, the central part of the retina, leading to vision problems in people with diabetes. The drug is administered as an eye drop and is intended to reduce retinal swelling.
Dexamethasone nanoparticles eye targets the glucocorticoid receptor, also known as NR3C1. Dexamethasone acts as an agonist at this receptor, meaning it activates it. This receptor is involved in regulating inflammation and immune responses, which is relevant to reducing the swelling associated with diabetic macular edema.
Dexamethasone nanoparticles eye is being developed by Oculis Holding AG, a biopharmaceutical company focused on ophthalmology. Oculis Holding AG trades under the ticker symbol OCS. The company is responsible for the clinical development of this nanoparticle eye drop formulation.
Dexamethasone nanoparticles eye is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA or any regulatory agency. The Phase 2 trial for diabetic macular edema has been completed, and further studies would be needed to support potential regulatory submissions.
Dexamethasone nanoparticles eye has been evaluated in one completed Phase 2 clinical trial, NCT05343156, titled "Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema." The trial enrolled 144 participants and was an uncontrolled study, meaning it did not include a comparator group. No active trials are currently listed.
Yes, Dexamethasone nanoparticles eye and Dexamethasone nanoparticles eye drops refer to the same investigational product. The term "eye drops" describes the route of administration, while the shorter name is often used in clinical and regulatory contexts. Both names refer to the nanoparticle formulation of dexamethasone developed by Oculis Holding AG.